HLB Genex, Inc. (KOSDAQ:187420)

Market Cap	77.39B -41.8%
Revenue (ttm)	40.95B +17.6%
Net Income	-3.28B
EPS	-116.48
Shares Out	29.20M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	69,092
Average Volume	134,321
Open	2,700.00
Previous Close	2,685.00
Day's Range	2,640.00 - 2,705.00
52-Week Range	2,525.00 - 4,645.00
Beta	0.03
RSI	40.94
Earnings Date	Nov 14, 2025

About HLB Genex

HLB Genex, Inc. engages in the research and development, production, import/export, and sale of enzymes and fermentation products in South Korea and internationally. Its industrial special enzyme products include lactase; catalase for use in semiconductor industry; and proteinase K for molecular diagnostics and genetic engineering experiments, as well as bio-health care ingredients comprise N-phytosphingosine and vitamin K2. The company also develops drug candidates for wet and dry macular degeneration, inflammatory bowel disease, anticancer, o...

• Industry: Industrial Organic Chemicals
• Founded: 2000
• Employees: 75
• Stock Exchange: KOSDAQ
• Ticker Symbol: 187420

Financial Performance

In 2024, HLB Genex's revenue was 35.43 billion, an increase of 31.18% compared to the previous year's 27.01 billion. Losses were -18.83 billion, 538.2% more than in 2023.